Concepedia

Author

Jean‐Charles Soria

Institut Gustave RoussyORCID

Also Known As

D Planchard, J -C Soria, J C Soria, J Soria, J-C Soria, J. -C. Soria, J. C. Soria, J. Soria, J.-C. Soria, J.C Soria

1.6K

Publications

89K

Citations

128

H-Index

236

Concepts

All Affiliations

Institut Gustave RoussyInsermUniversité Paris-SaclayUniversité Paris-SudCentre National de la Recherche Scientifique
JS

About

Jean‐Charles Soria is an author at Institut Gustave Roussy specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

72

248

28.2K

2

Health Sciences

27

53

4K

3

Natural Sciences

6

6

291

4

Engineering

4

4

2.1K

5

Public Health

4

4

451

Jean‐Charles Soria

×

421

Publications

71.1K

Citations

112

H-Index

YearCitations

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui,

New England Journal of Medicine

2015

6.1K

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz,

Nature

2014

5.2K

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa,

Science

2017

5.2K

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste,

New England Journal of Medicine

2017

5K

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard,

New England Journal of Medicine

2019

2.7K

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

Ken A. Olaussen, Ariane Dunant, Pierre Fouret,

New England Journal of Medicine

2006

1.7K

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

Martin Peifer, Lynnette Fernandez‐Cuesta, Martin L. Sos,

Nature Genetics

2012

1.4K

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou,

The Lancet Oncology

2018

1.2K

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari,

Clinical Cancer Research

2016

1.2K

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari,

The Lancet

2017

1.1K

Page 1